References
- Younossi ZM, Blissett D, Blissett R, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology. 2016;64:1577–1586.
- Harrison SA, Gawrieh S, Roberts K, et al. Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort. J Hepatol. 2021;75:284–291.
- Povsic M, Wong OY, Perry R, et al. A structured literature review of the epidemiology and disease burden of non-alcoholic steatohepatitis (NASH). Adv Ther. 2019;36:1574–1594.
- Noureddin M, Vipani A, Bresee C, et al. NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances. Am J Gastroenterol. 2018;113:1649–1659.
- Ekstedt M, Nasr P, Kechagias S. Natural History of NAFLD/NASH. Curr Hepatol Rep. 2017;16:391–397.
- Kupčová V, Fedelešová M, Bulas J, et al. Overview of the pathogenesis, genetic, and non-invasive clinical, biochemical, and scoring methods in the assessment of NAFLD. Int J Environ Res Public Health. 2019;16:3570.
- Loomba R, Adams LA. The 20% rule of NASH progression: the natural history of advanced fibrosis and cirrhosis caused by NASH. Hepatology. 2019;70:1885–1888.
- Hossain N, Afendy A, Stepanova M, et al. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7:1224–1229.e2.
- Nakamura S, Konishi H, Kishino M, et al. Prevalence of esophagogastric varices in patients with non-alcoholic steatohepatitis. Hepatol Res. 2008;38:572–579.
- Mantovani A, and Tsochatzis EA. Epidemiology of varices and variceal bleeding in liver cirrhosis. In: Variceal bleeding in liver cirrhosis. Singapore: Springer Singapore; 2021;1–11 .
- Vaz J, Eriksson B, Strömberg U, et al. Incidence, aetiology and related comorbidities of cirrhosis: a Swedish population-based cohort study. BMC Gastroenterol. 2020;20. DOI:https://doi.org/10.1186/s12876-020-01239-6
- Hsu S-J, Huang H-C. Management of ascites in patients with liver cirrhosis: recent evidence and controversies. J Chin Med Assoc. 2013;76:123–130.
- Planas R, Montoliu S, Ballesté B, et al. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol. 2006;4:1385–1394.e1.
- Elsaid MI, Rustgi VK. Epidemiology of hepatic encephalopathy. Clin Liver Dis. 2020;24:157–174.
- Noureddin M, Rinella ME. Nonalcoholic fatty liver disease, diabetes, obesity, and hepatocellular carcinoma. Clin Liver Dis. 2015;19:361–379.
- Mittal S, El-Serag HB, Sada YH, et al. Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2016;14(1):124–131.e1.
- Negro F. Natural history of NASH and HCC. Liver Int. 2020;40:72–76.
- Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology. 2010;51:1820–1832.
- Ascha MS, Hanouneh IA, Lopez R, et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 2010;51:1972–1978.
- Brunt EM, Kleiner DE, Wilson LA, et al. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology. 2011;53:810–820.
- Sumida Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol. 2014;20:475.
- Vuppalanchi R, Ünalp A, van Natta ML, et al. Effects of liver biopsy sample length and number of readings on sampling variability in nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7:481–486.
- Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005;128:1898–1906.
- Younossi Z, Stepanova M, Sanyal AJ, et al. The conundrum of cryptogenic cirrhosis: adverse outcomes without treatment options. J Hepatol. 2018;69:1365–1370.
- Noureddin M, Chan JL, Barradas K, et al. Attribution of nonalcoholic steatohepatitis as an etiology of cirrhosis for clinical trials eligibility: recommendations from the multi-stakeholder liver forum. Gastroenterology. 2020;159:422–427.e1.
- Liang Y, Li D. Magnetic resonance elastography in staging liver fibrosis in non-alcoholic fatty liver disease: a pooled analysis of the diagnostic accuracy. BMC Gastroenterol. 2020;20. DOI:https://doi.org/10.1186/s12876-020-01234-x
- Idilman IS, Aniktar H, Idilman R, et al. Hepatic steatosis: quantification by proton density fat fraction with mr imaging versus liver biopsy. Radiology. 2013;267:767–775.
- Tang A, Tan J, Sun M, et al. Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis. Radiology. 2013;267:422–431.
- Loomba R, Neuschwander‐Tetri BA, Sanyal A, et al. Multicenter validation of association between decline in MRI‐PDFF and histologic response in NASH. Hepatology. 2020;72:1219–1229.
- Tamaki N, Munaganuru N, Jung J, et al. Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease. Gut. 2021:gutjnl-2021-324264. DOI:https://doi.org/10.1136/gutjnl-2021-324264
- Caussy C, Reeder SB, Sirlin CB, et al. Noninvasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials. Hepatology. 2018;68:763–772.
- Siddiqui MS, Vuppalanchi R, van Natta ML, et al. Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2019;17:156–163.e2.
- Regulatory Perspectives for Development of Drugs for Treatment of NASH [Internet]; 2018. 22 Aug 2021 Available from: https://www.fda.gov/drugs/news-events-human-drugs/regulatory-perspectives-development-drugs-treatment-nash-01292021-01292021
- Harrison SA, Abdelmalek MF, Caldwell S, et al. Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis. Gastroenterology. 2018;155:1140–1153.
- Harrison SA, Wong VW-S, Okanoue T, et al. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials. J Hepatol. 2020;73:26–39.
- Sanyal A, Anstee Q, Trauner M, et al. Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis. Hepatology. 2020;72:67A–68A.
- Rinella ME, Noureddin M. STELLAR 3 and STELLAR 4: lessons from the fall of Icarus. J Hepatol. 2020;73:9–11.
- Younossi ZM, Ratziu V, Loomba R, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019;394:2184–2196.
- DeFrancesco L, Frates C. Intercept completes enrollment of Phase 3 reverse study evaluating obeticholic acid for the treatment of compensated cirrhosis due to NASH [Internet]; [cited 2021 Aug 21]. Available from: https://ir.interceptpharma.com/news-releases/news-release-details/intercept-completes-enrollment-phase-3-reverse-study-evaluating
- Chalasani N, Abdelmalek MF, Garcia-Tsao G, et al. Effects of belapectin, an inhibitor of Galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension. Gastroenterology. 2020;158:1334–1345.e5.
- Harrison SA, Marri SR, Chalasani N, et al. Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis. Aliment Pharmacol Ther. 2016;44:1183–1198.
- Study evaluating the efficacy and safety of belapectin for the prevention of esophageal varices in NASH cirrhosis (NAVIGATE) [Internet]; [cited 2021 Aug 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT04365868?intr=belapectin&draw=2&rank=2
- Study of aldafermin (NGM282) in subjects with compensated cirrhosis (ALPINE 4) [Internet]; [cited 2021 Aug 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT04210245
- NGM bio reports topline results from 24-week Phase 2b ALPINE 2/3 study of aldafermin in NASH [Internet]. Globalnewswire.com; 2021 [cited 2021 Aug 21]. Available from: https://www.globenewswire.com/news-release/2021/05/24/2234585/35057/en/NGM-Bio-Reports-Topline-Results-from-24-Week-Phase-2b-ALPINE-2-3-Study-of-Aldafermin-in-NASH.html
- Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4); 2021.
- Sanyal A, Charles ED, Neuschwander-Tetri BA, et al. Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial. Lancet. 2018;392:2705–2717.
- Abdelmalek MF, Charles ED, Sanyal AJ, et al. The FALCON program: two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis. Contemp Clin Trials. 2021;104:106335.
- Harrison SA, Ruane PJ, and Freilich BL, et al. Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial. Nat Med. 2021;27:1262–1271.
- Harrison S, Ruane P, Freilich B, et al. Efruxifermin (EFX) improved markers of fibrosis, liver injury and metabolism in F4 NASH patients with compensated cirrhosis. J Hepatol. 2021;75:S204–S205.
- Tartaglia C. akero announces positive histological improvements in cirrhotic NASH (F4) patients after 16 weeks in extension cohort C [Internet]. AkeroTx; 2021 [cited 2021 Aug 21]. Available from: https://ir.akerotx.com/news-releases/news-release-details/akero-announces-positive-histological-improvements-cirrhotic
- A study of efruxifermin in non-cirrhotic subjects with histologically confirmed nonalcoholic steatohepatitis (NASH) (Harmony) [Internet]; [cited 2021 Aug 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT04767529?intr=efruxifermin&draw=2&rank=1
- Tartaglia C. Akero therapeutics initiates Phase 2b HARMONY study of efruxifermin (EFX) for the treatment of NASH [Internet]; 2021 [cited 2021 Aug 21]. Available from: https://ir.akerotx.com/news-releases/news-release-details/akero-therapeutics-initiates-phase-2b-harmony-study-efruxifermin
- A study of efruxifermin in subjects with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH) (Symmetry); 2021.
- Harrison SA, Bashir MR, Guy CD, et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2019;394:2012–2024.
- Resmetirom (MGL-3196) [Internet]; [cited 2021 Aug 22]. Available from: https://www.madrigalpharma.com/ourapproach/mgl3196/
- A Phase 3 study to evaluate the efficacy and safety of MGL-3196 (Resmetirom) in patients with NASH and fibrosis (MAESTRO-NASH) [Internet]; [cited 2021 Aug 22]. Available from: https://clinicaltrials.gov/ct2/show/NCT03900429
- A Phase 3 study to evaluate the safety and biomarkers of resmetirom (MGL-3196) in non alcoholic fatty liver disease (NAFLD) patients (MAESTRO-NAFLD1) [Internet]; [cited 2021 Aug 22]. Available from: https://clinicaltrials.gov/ct2/show/NCT04197479
- Loomba R, Noureddin M, Kowdley KV, et al. Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis attributable to NASH. Hepatology. 2021;73:625–643.
- Taylor‐Weiner A, Pokkalla H, Han L, et al. A machine learning approach enables quantitative measurement of liver histology and disease monitoring in NASH. Hepatology. 2021;74:133–147.
- Study evaluating the safety and efficacy of semaglutide, and the fixed-dose combination of cilofexor and firsocostat, alone and in combination, in participants with compensated cirrhosis (F4) due to nonalcoholic steatohepatitis (NASH) 23 Aug 2021 [Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT04971785?intr=firsocostat&draw=2&rank=3
- Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149:389–397.e10.
- Vilar-Gomez E, Calzadilla-Bertot L, Wai-Sun Wong V, et al. Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study. Gastroenterology. 2018;155:443–457.e17.
- Hytiroglou P, Theise ND. Regression of human cirrhosis: an update, 18 years after the pioneering article by Wanless et al. Virchows Arch. 2018;473:15–22.
- Lindor KD, Jorgensen RA, Therneau TM, et al. Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis. Mayo Clin Proc. 1997;72:1137–1140.
- Merkel C, Marin R, Angeli P, et al. A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis. Gastroenterology. 2004;127:476–484.
- Petta S, Sebastiani G, and Bugianesi E, et al. Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis. J Hepatol. 2018;69:878–885.
- Bosch J, Chung C, Carrasco‐Zevallos OM, et al. A machine learning approach to liver histological evaluation predicts clinically significant portal hypertension in NASH cirrhosis. Hepatology. 2021;74:3146–3160.
- Gidener T, Ahmed OT, Larson JJ, et al. Liver stiffness by magnetic resonance elastography predicts future cirrhosis, decompensation, and death in NAFLD. Clin Gastroenterol Hepatol. 2021;19:1915–1924.e6.
- Han MAT, Vipani A, Noureddin N, et al. MR elastography‐based liver fibrosis correlates with liver events in nonalcoholic fatty liver patients: a multicenter study. Liver Int. 2020;40:2242–2251.
- Adams LA, Lymp JF, St. Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129:113–121.